Rhumbline Advisers Lowers Position in Rhythm Pharmaceuticals, Inc. $RYTM

Rhumbline Advisers lessened its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.2% in the third quarter, HoldingsChannel.com reports. The fund owned 82,068 shares of the company’s stock after selling 5,458 shares during the period. Rhumbline Advisers’ holdings in Rhythm Pharmaceuticals were worth $8,288,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of RYTM. AQR Capital Management LLC lifted its position in Rhythm Pharmaceuticals by 148.2% during the first quarter. AQR Capital Management LLC now owns 39,363 shares of the company’s stock valued at $2,085,000 after purchasing an additional 23,506 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Rhythm Pharmaceuticals by 6.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,282 shares of the company’s stock worth $1,874,000 after buying an additional 2,126 shares during the last quarter. CWM LLC raised its position in shares of Rhythm Pharmaceuticals by 19.6% during the 2nd quarter. CWM LLC now owns 3,091 shares of the company’s stock valued at $195,000 after buying an additional 507 shares in the last quarter. Allianz Asset Management GmbH lifted its holdings in shares of Rhythm Pharmaceuticals by 98.4% during the 2nd quarter. Allianz Asset Management GmbH now owns 12,100 shares of the company’s stock worth $765,000 after acquiring an additional 6,000 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in Rhythm Pharmaceuticals by 3.0% in the second quarter. Teacher Retirement System of Texas now owns 12,772 shares of the company’s stock worth $807,000 after acquiring an additional 368 shares in the last quarter.

Wall Street Analyst Weigh In

RYTM has been the topic of a number of research reports. The Goldman Sachs Group raised their price target on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the company a “buy” rating in a research report on Friday, December 12th. HC Wainwright boosted their target price on Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Wall Street Zen lowered Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Guggenheim increased their price target on shares of Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Rhythm Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $131.50.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This trade represents a 3.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the transaction, the insider owned 20,814 shares in the company, valued at $2,310,354. The trade was a 13.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 25,003 shares of company stock valued at $2,589,015 over the last quarter. 6.10% of the stock is currently owned by company insiders.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC/ Royal Bank initiated coverage and/or upgraded RYTM with an outperform/moderate-buy stance, bringing renewed institutional attention and a formal buy-style endorsement that can support near-term demand. RBC initiates coverage
• Positive Sentiment: Several sell-side firms have raised price targets and reiterated buy/overweight ratings (Wells Fargo, Morgan Stanley, Citizens/JMP, UBS, TD Cowen), reinforcing a bullish consensus and higher upside expectations. MarketBeat analyst roundup
• Positive Sentiment: Operational narrative improving: a Yahoo Finance piece highlights Imcivree revenue ramp and updated management targets — if execution continues, this supports medium-term revenue growth that underpins analyst optimism. Imcivree revenue and targets
• Neutral Sentiment: Zacks moved coverage from “strong sell” to “hold” and flagged RYTM as positioned to potentially beat upcoming earnings — these are watchpoints that reduce perceived downside but are not immediate catalysts without reported results. Zacks coverage and earnings outlook
• Negative Sentiment: Insider selling by CFO Hunter C. Smith: filings show sales of several thousand shares (transactions reported for Feb. 17 and Feb. 19 at ~ $101 per share). While the amounts are a small percentage of his total holding, such sales can trigger near-term selling pressure or investor concern about insider conviction. CFO sale disclosure

Rhythm Pharmaceuticals Price Performance

Shares of Rhythm Pharmaceuticals stock opened at $99.78 on Friday. Rhythm Pharmaceuticals, Inc. has a one year low of $45.90 and a one year high of $122.20. The business’s 50 day simple moving average is $105.41 and its two-hundred day simple moving average is $103.40. The stock has a market capitalization of $6.66 billion, a P/E ratio of -32.19 and a beta of 2.00.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.